SPRB

News

businesswire.comSpruce Biosciences Announces Long-Term Tralesinidase Alfa Enzyme Replacement Therapy Data in Sanfilippo Syndrome Type B (MPS IIIB) Presented at the 18th International MPS Symposiumbusinesswire.comJun 8

businesswire.comSpruce Biosciences Announces Data Presentation at the 18th International MPS Symposiumbusinesswire.comMay 28

businesswire.comSpruce Biosciences to Participate in Upcoming Conferences in Junebusinesswire.comMay 27

gurufocus.comSpruce Biosciences Reports First Quarter 2026 Financial Results and Provides Corporate Updatesgurufocus.comMay 13

businesswire.comSpruce Biosciences Reports First Quarter 2026 Financial Results and Provides Corporate Updatesbusinesswire.comMay 13

Trade SPRB

About Spruce Biosciences, Inc.

Spruce Biosciences, Inc., founded in 2014 and situated in Daly City, California, operates as a biopharmaceutical enterprise. Its primary objective is to advance and bring to market innovative treatments, particularly for uncommon endocrine conditions. A central component of its therapeutic pipeline is tildacerfont, a non-steroidal drug candidate. This compound is currently undergoing Phase 2b clinical assessments in adult patients with congenital adrenal hyperplasia (CAH), with the aim of optimizing disease management and lessening dependence on steroid medications by examining reductions in glucocorticoid levels and their clinical consequences. Tildacerfont is also progressing through Phase 2 trials for pediatric classic CAH, as well as investigating its efficacy in women suffering from polycystic ovary syndrome (PCOS). Additionally, Spruce Biosciences maintains a collaborative licensing agreement with Eli Lilly and Company to jointly explore, formulate, and commercialize various pharmaceutical substances.

CEO: Javier Szwarcberg
IPO Date: Oct 9, 2020

Market Data

Open: $49.91
High: $53.25
Low: $49.02
Volume: 80.9K
52W High: $838.13
52W Low: $7.00

Valuation

Market Cap: $71M
Enterprise Value: $24M

Financials

Free Cash Flow: $-33M
Revenue: $0
Net Income: $-39M
Cash: $49M
Debt: $736k

Events

EarningsAug 13

EPS est. -5.655